Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS?
Posted:
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS) after allegations that the drug was approved despite internal concerns about its efficacy in women and a potential increased risk of breast cancer.
Buckinghamshire Healthcare NHS Trust has become the first NHS organisation to sign a contract with System C to implement its CareFlow Ambient AI Outpatient Consultations module, with go-live planned for Summer 2026.
Read more here.
Whole-body diffusion-weighted MRI (WB-DWI/MRI) after neoadjuvant chemotherapy (NACT) predicted complete resection at interval debulking surgery (IDS) with more than 93% accuracy in patients with advanced ovarian cancer while demonstrating superior performance over CT.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us